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Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease M. Sako *, T. Kawaguchi, A. Hirayama, G. Fukushi, K. Hayama, T. Fujiwara, N. Yoshimura, M. Takazoe. Social Insurance Central Hospital, Centre for Inflammatory Bowel Disease, Tokyo, Japan Background: The scheduled maintenance therapy of infliximab (IFX) for Crohn's disease (CD) may require dose escalation due to secondary loss of efficacy. There are limited data on the response to an intensified infliximab regimen for Japanese patients with CD. Methods: We performed a retrospective survey of 35 patients with CD who had received IFX 5 mg/kg every 5 7 weeks and has begun infusion of IFX 10 mg/kg. They received IFX therapy in extended intervals if duration period of the drug get longer. We analyzed the proportion of the patients who could extend the intervals of IFX therapy. Results: Rapid clinical response was observed in 15/35 patients (42.9%) and they could extend intervals of infusion in one year. Among 29 patients followed over 24 months, 20.7% (6/29) were maintained in clinical remission with IFX given every 8 weeks at 12 months and 34.5% (10/29) at 24 months after the dose adjustment. 57.1% (20/35) of the patients had no change in duration of response to IFX. 7/20 patients stopped IFX therapy because of the need for surgical resection (5 patients, 4 of them continued IFX 5 mg/kg every 8 weeks after surgery), or symptoms of intestinal stenosis, no response (one patient, respectively). Two patients experienced gradual loss of efficacy. Azathioprine was used concomitantly in 5/20 patients who showed poor response to escalation, yet in resoponders, there was no concomitant treatment with immunomodulatory agents. Patients who could get longer intervals of IFX had started dose escalation earlier compared with those who had showed poor response (15.5±10.2 months vs. 41.5±18.7 months from the beginning of initial IFX therapy, p < 0.05). The CDAI of the patients achieving response were relatively lower (158±96.1) at the beginning of dose intensification than the poor responders (181±63.4). There was no disparity between them in C-reactive protein at dose escation (1.5 mg/L vs. 1.7 mg/L). Conclusions: 42.9% of the patients successfully extended duration of efficacy of IFX within 2 years after dose escalation. Early intensification of IFX might lead higher rate of early remission induction.
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Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5 years from a tertiary referral center L. Ramos *, A. Hernandez Camba, M. Carrillo Palau, I. Alonso, N. Hernandez Alvarez-Buylla, E. Quintero Carrion.
Hospital Universitario de Canarias, Gastroenterology, La Laguna, SantaCruz de Tenerife, Spain
Background: Over the past decade, biological agents as anti-TNF antagonists (aTNFa) have become available as effective treatment for inducing and mantaining clinical remission in luminal and fistulising Crohn's disease (CD). Several large trials have demostrated its efficacy and safety but just during a limited follow-up period. However, few data are available regarding clinical practice and the use of aTNFa. The aim of this study was to evaluate the efficacy and safety of aTNFa during a 5 years-period in a single center. Methods: All consecutive CD patients receiving aTNFa between January 2007 and December 2012 were retrospectively reviewed untill June 2013. Data regarding time from diagnosis, site of disease, previous medication and indication of aTNFa were collected. Initial and sustained clinical response was evaluated at 3 6 month and at the end of follow-up. Cause of biological discontinuation and adverse effects related to aTNFa were evaluated. Rate of corticosteroids use, hospitalizations and surgery during and after aTNFa were registered. Results: A total of 117 CD patients (60M/57F, mean age 40.3 years; Infliximab [IFX] n = 86, Adalimumab [ADA] n = 31) were included. The main indication for aTNFa was corticodependency (40%), associated to immunomodulators (89%). Median follow-up lenght was 40.3 months (±12). Five patients received only induction therapy. Mean time of aTNFa treatment was 25 months (±21). Initial clinical response were showed in 72% and 75% of patients at 3 and 6 months, respectively. Significative reduction of PCR levels was determinated after 1 year (23.4±34 vs 8.4±20; p < 0.001). aTNTa was discontinued in 62 (53%) patients (55IFX/7ADA): 11% due to side effects (12 anaphylaxias and 1 tuberculosis-no mortality reported), 13% for loss of response and 21% (25) for clinical remission. Twentyfour patients changed biological agent and mantained clinical efficacy. After aTNFa discontinuation for clinical remission, the rate of relapse and new indication of aTNFa was 16% (4/25) after a follw-up time of 19±13 months.
Conclusions:
In our series, aTNFa therapy was very efficacious to obtain clinical response during the first year of treatment (75% 6 months). Clinical remission determined biological discontinuation in 20% of patients, requiring new indication of aTNFa in 16% of these cases after 19 months. Use of aTNFs was safe in our population after a follow-up of 40 months.
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